Among many functions that wound management products might offer — wound closure, wound sealing, anti-infection, anti-adhesion, etc. — hemostasis represents a function that offers entry to the market by manufacturers of products derived from thrombin, gelatin, platelets, collagen, fibrin, fibrinogen, synthetics, etc.
Ideally, products offer multiple functions that will result in effectively closed and healed wounds with few complications. Nonetheless, the urgency with which bleeding must be stopped in acute wounds has driven the development of products that demonstrate important clinical utility simply by focusing on hemostasis rather than comprehensive wound management.
As a result, a good number of companies have emerged and become successful in the hemostasis niche.
Below is illustrated the distribution of companies active in marketing and/or developing products in hemostasis.
Source: MedMarket Diligence, LLC; Report #S190.